(Q38019976)

27 August 2017

title

Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer (English)

1 reference

27 August 2017

1 reference

3

1 reference

27 August 2017

Raffaele Califano

1

1 reference

27 August 2017

Lorenza Landi

series ordinal

2

1 reference

27 August 2017

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72 Suppl 1

1 reference

27 August 2017

page(s)

28-36

1 reference

https://scigraph.springernature.com/pub.10.2165/1163012-s0-000000000-00000

27 August 2017

exact match

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Implications and prognostic value of K-ras mutation for early-stage lung cancer in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163012-S0-000000000-00000

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status

21 January 2018

1 reference

12 December 2020

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

1 reference

12 December 2020

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

1 reference

12 December 2020

ras oncogenes in human cancer: a review

1 reference

12 December 2020

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

1 reference

12 December 2020

Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers

1 reference

12 December 2020

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

12 December 2020

Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung

1 reference

12 December 2020

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

1 reference

12 December 2020

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

12 December 2020

10.2165/1163012-S0-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1013535451

0 references

1 reference